AIRNA Corporation

https://www.airna.com

AIRNA is pioneering the discovery and development of RNA editing therapeutics to transform the lives of patients with rare and common diseases. RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be conveniently re-dosed and manufactured. Our RESTORE+™ platform is based on groundbreaking research by academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), who were the first to elucidate a therapeutic approach for precise editing of RNA. AIRNA is advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well as a pipeline of therapeutic candidates to address multiple diseases with high unmet need. AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany. *

	Start	2024-07-31 existent
	Group	AIRNA (Group)
	Industry	RNA-based therapeutic
	Industry 2	RESTORE+™ RNA editing platform
	Person	Elverum, Kris (AIRNA 202309 CEO before Diagon Therapeutics + Rubius Therapeutics + Turnstone Biologics + SQZ Biotech)
	Person 2	Novak, Rodger (CRISPR Therapeutics 201712– Board Chairman 2013–201711 CEO + Co-Founder before Sanofi + Nabriva GmbH)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	238 Main Street c/o Bayer Co.Lab
	City	02142 Cambridge, MA
		Address record changed: 2024-07-31

Basic data	Employees	n. a.

		* Document for »About Section«: AIRNA Corporation. (7/31/24). "Press Release: AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic". Cambridge, MA & Tübingen.

		Record changed: 2024-07-31